Developer docs
API playgroundTry for free, no card

Search company profiles

Kenvue

Full company profile

uuid000068x

Namestring
Kenvue
Legal namestring
Kenvue Inc.
Websiteurl
kenvue.com
Company typeenum
Public
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersSummit, United States
HQ citystring
Summit
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices15 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
consumer health products, over-the-counter medicines, skincare and beauty, oral care products, personal care brands
Industry1 code
PRIMARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code1 code
  • Other Health and Personal Care Retailers45619
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Perfumes, Cosmetics & Other Toilet Preparations2844
Product category
Consumer Health Products
Social media profiles4 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Self Care (OTC Medicines)
TypeTransaction Fee
Description

Over-the-counter medicines including Tylenol, Motrin, Benadryl, Zyrtec, and Nicorette generating revenue through retail pharmacy and consumer purchases. Segment reported 1.9% growth in Q1 2026.

stocktitan.net
2Skin Health and Beauty
TypeTransaction Fee
Description

Skincare and beauty products including Neutrogena, Aveeno, OGX, and Rogaine. Segment led performance with 8.4% net sales growth in Q1 2026, supported by innovations including Neutrogena Sun Care expansion.

globalcosmeticsnews.com
3Essential Health
TypeTransaction Fee
Description

Essential health products including Listerine, Band-Aid, Johnson's Baby, and Imodium. Segment grew 4.9% in Q1 2026.

stocktitan.net
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure
Pricing details1 tier
1Dividend Aristocrat with 63 consecutive years of dividend increases
ModelSubscriptionBilling cadenceQuarterly
Notes

Quarterly dividend of $0.2075 per share, representing approximately 4.5-4.9% yield based on stock trading in mid-$18 range

fool.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 19 records shown
1Listerine
Description

Oral care mouthwash brand; alcohol-based antiseptic product for reducing plaque and freshening breath.

kenvue.com
+18 more records
Core offering1 text field

Kenvue is the world's largest pure-play consumer health company, manufacturing and marketing a portfolio of iconic over-the-counter medicines, skincare, oral care, baby care, and personal health brands. The company operates across three segments — Self Care (Tylenol, Motrin, Benadryl, Zyrtec, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX, Rogaine), and Essential Health (Listerine, Band-Aid, Johnson's Baby) — distributing products to approximately 1.2 billion consumers across more than 165 countries through retail pharmacies, drugstores, and e-commerce channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 8.4% net sales growth in Skin Health and Beauty segment Q1 2026
+4 more records
Product overview1 text field

Kenvue is the world's largest pure-play consumer health company, operating as a multi-brand portfolio organized across three segments: Self Care (over-the-counter medicines like Tylenol, Benadryl, Zyrtec, Sudafed, Nicorette, and Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX, Rogaine, Clean & Clear, and Zarbees), and Essential Health (Band-Aid, Johnson's Baby, and Calpol). The company markets Listerine for oral care and Benylin for cold symptoms. Brands are distributed globally across retail and e-commerce channels, backed by clinical research and healthcare professional endorsements. Founded in 2022 and spun off from Johnson & Johnson in 2023, Kenvue touches the lives of approximately 1.2 billion consumers across over 165 countries.

Product and service1 record
1Tylenol
Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Pilot program called Electric Loop (eLoop) testing electric freight delivery across select urban routes in Greater Toronto Area. Electric truck deployment on short-haul routes evaluating real-world operational performance, energy efficiency, and emissions impact in dense city conditions.

2Asia Pacific Dental Federation
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-25
Description

Kenvue (makers of LISTERINE) supported landmark white paper on evidence-based daily oral self-care guidelines. Report highlights brushing reaches only 25% of mouth surfaces; therapeutic mouthwash reduces plaque by 25-50% and gum bleeding by up to 67.8%.

thehindu.com
3Greyparrot
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-20
Description

Strategic collaboration leveraging Greyparrot's Deepnest AI platform to analyze and validate packaging performance in real-world recycling facilities in UK and US. Moves beyond theoretical design-for-recycling to actual recovery data, enabling packaging circularity improvements and EPR cost forecasting.

sustainabilityonline.net
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-07
Description

Multi-year collaboration to modernize digital and data capabilities, aligning dermatologist education, AI-driven insights, and e-commerce execution to support Kenvue's innovation strategy.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Collaboration on World Hand Hygiene Day and 'No Fear of Diarrhoea' initiative in Kanpur district, India. Health Department partnership distributing ORS packets and demonstrating proper handwashing techniques.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-05-01
Description

Retail media partnership where Kenvue leverages CVS's CorIQ AI platform for media planning, real-time optimization, and measurement. Kenvue achieved 30% or greater lift in buyer conversion and basket size through the partnership.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Collaboration with Kenvue for consumer health products, announced alongside Essex's strategic partnerships for distribution including Beifushu entering Singapore market and MOU with Suzhou Industrial Park for life sciences accelerator.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Three-year research collaboration with Aveeno brand focusing on skin health science including preclinical and clinical investigations on skin longevity and regeneration. Builds on 80-year history of collaboration dating to 1945 when Musher brothers worked with Mayo Clinic to develop colloidal oatmeal treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Kimberly-Clark announced plans to acquire Kenvue for approximately $48.7 billion enterprise value, creating a combined entity with ~$32 billion in revenue and $7 billion EBITDA pre-synergies. Deal approved by shareholders in January 2026 with CCI approval in India; expected to close H2 2026. Kenvue shareholders to receive $3.50 per share plus 0.14625 Kimberly-Clark shares per share.

10Sonoma Pharmaceuticals
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-01
Description

Manufacturing and Supply Agreement for Microcyn technology-based products in US, effective October 2025 through March 2027 with potential extensions. Sonoma also launching new dermatology products and burn relief hydrogel in US retail stores.

in.investing.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Church & Dwight (NYSE: CHD) operates in personal care, household, and specialty consumer health with brands including Orajel (oral pain relief competing with Anbesol/Tylenol Oral), Batiste (dry shampoo), and Trojan. The diversified consumer health orientation and North American retail distribution model align closely with Kenvue's approach.

TypeBroad incumbent
Description

P&G (NYSE: PG) is a diversified CPG incumbent with overlapping brands including Vicks (OTC cold), Pepto-Bismol (digestive), Align (probiotics), Oral-B (oral care), and Gillette (personal care). While P&G is much broader than Kenvue, the consumer health portfolio competes directly across most of Kenvue's Self Care and Essential Health segments.

TypeDirect peer
Description

Reckitt (LSE: RKT) operates a Health segment (Mucinex, Delsym, Nurofen, Gaviscon) that directly competes with Kenvue's OTC franchise, plus Hygiene (Lysol, Dettol) and Home care. Reckitt is one of the closest pure-play comparables to Kenvue's OTC + hygiene orientation with similar pharmacy channel distribution.

TypeDirect peer
Description

L'Oréal (EPA: OR) is the world's largest beauty company with dermatological brands (CeraVe, La Roche-Posay, Vichy) directly competing with Kenvue's Neutrogena and Aveeno franchises. The Skin Health and Beauty segment faces its most formidable competitor in L'Oréal's Active Cosmetics division, which has captured significant clinical skincare share.

TypeDirect peer
Description

Estée Lauder (NYSE: EL) operates premium skincare and beauty brands (Estée Lauder, Clinique, La Mer) competing with Kenvue's Neutrogena in mass-to-prestige skincare. While more premium-focused, Estée Lauder's dermatological skincare investments and global beauty distribution create direct competitive pressure on Kenvue's Skin Health and Beauty growth.

TypeDirect peer
Description

Haleon (NYSE: HLN) is the world's other major pure-play consumer health company, spun off from GSK in 2022. It directly competes with Kenvue across OTC (Advil vs Tylenol, Centrum vs Flintstones), oral health (Sensodyne vs Listerine adjacent categories), and respiratory health (Panadol, Voltaren). Both companies share the same pure-play consumer health DNA, pharmacy distribution model, and brand-driven growth strategy.

TypeDirect peer
Description

Beiersdorf (XETRA: BEI) is a global skincare leader with Nivea, Eucerin, La Prairie, and Hansaplast directly competing with Kenvue's Neutrogena, Aveeno, and Band-Aid franchises. The dermatological positioning, OTC adjacency (Eucerin), and global skincare scale make Beiersdorf a direct peer in Skin Health and Beauty and wound care.

8Bayer Consumer Health
TypeDirect peer
Description

Bayer's Consumer Health division (part of XETRA: BAYN) includes Aspirin, Claritin, Aleve, and Coppertone (now sold to Kenvue-aligned brands), directly competing with Kenvue's pain relief, allergy, and sun care franchises. The portfolio overlap in OTC analgesics and sun protection makes Bayer Consumer Health a direct comparable.

TypeBroad incumbent
Description

Johnson & Johnson (NYSE: JNJ) was Kenvue's parent company until the May 2023 spin-off and continues to operate in adjacent consumer health-adjacent categories through its pharma and medtech segments. While J&J divested its consumer health business, the historical parent relationship, overlapping R&D heritage, and ongoing competitive dynamics make J&J a relevant broad incumbent comparable.

TypeDirect peer
Description

Colgate-Palmolive (NYSE: CL) is the global oral care leader (Colgate, Tom's of Maine, meridol) directly competing with Kenvue's Listerine franchise, plus personal care (Palmolive, Softsoap) overlapping with Kenvue's body care brands. The business model alignment and shared retail channels make Colgate one of Kenvue's most direct competitors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries12 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kenvue

Consumer Health Productskenvue.com

Kenvue firmographics

Firmographics
Name
Kenvue
Legal name
Kenvue Inc.
Website
https://kenvue.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
10,001+ employees
Ownership category
akta.pro rank

Kenvue industry classification

Industry
Product category
Consumer Health Products
NAICS
Other Health and Personal Care Retailers (45619)
SIC
Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro industry
PRIMARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Consumer health products
  • Over-the-counter medicines
  • Skincare and beauty
  • Oral care products
  • Personal care brands

Where Kenvue is headquartered

Location

Headquarters

HQ city
Summit
HQ country
United States
HQ region
North America

Offices15 records

Markets served

Kenvue business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

  1. Self Care (OTC Medicines): Over-the-counter medicines including Tylenol, Motrin, Benadryl, Zyrtec, and Nicorette generating revenue through retail pharmacy and consumer purchases. Segment reported 1.9% growth in Q1 2026.
  2. Skin Health and Beauty: Skincare and beauty products including Neutrogena, Aveeno, OGX, and Rogaine. Segment led performance with 8.4% net sales growth in Q1 2026, supported by innovations including Neutrogena Sun Care expansion.
  3. Essential Health: Essential health products including Listerine, Band-Aid, Johnson's Baby, and Imodium. Segment grew 4.9% in Q1 2026.

Pricing tiers

ModelBillingPrice
SubscriptionQuarterlyDividend Aristocrat with 63 consecutive years of dividend increases

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Kenvue product offering

Product offering

Core offering

Kenvue is the world's largest pure-play consumer health company, manufacturing and marketing a portfolio of iconic over-the-counter medicines, skincare, oral care, baby care, and personal health brands. The company operates across three segments — Self Care (Tylenol, Motrin, Benadryl, Zyrtec, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX, Rogaine), and Essential Health (Listerine, Band-Aid, Johnson's Baby) — distributing products to approximately 1.2 billion consumers across more than 165 countries through retail pharmacies, drugstores, and e-commerce channels.

Product overview

Kenvue is the world's largest pure-play consumer health company, operating as a multi-brand portfolio organized across three segments: Self Care (over-the-counter medicines like Tylenol, Benadryl, Zyrtec, Sudafed, Nicorette, and Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX, Rogaine, Clean & Clear, and Zarbees), and Essential Health (Band-Aid, Johnson's Baby, and Calpol). The company markets Listerine for oral care and Benylin for cold symptoms. Brands are distributed globally across retail and e-commerce channels, backed by clinical research and healthcare professional endorsements. Founded in 2022 and spun off from Johnson & Johnson in 2023, Kenvue touches the lives of approximately 1.2 billion consumers across over 165 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Listerine: Oral care mouthwash brand; alcohol-based antiseptic product for reducing plaque and freshening breath.
  • Neutrogena
  • Aveeno
  • Band-Aid
  • Tylenol
  • Johnson's Baby
  • Zyrtec
  • OGX
  • Rogaine
  • Nicorette
  • Benadryl
  • Le Petit Marseillais
  • Imodium
  • Sudafed
  • Benylin
  • Calpol
  • Nicorette
  • Zarbees
  • Clean & Clear

Products and services

  • Tylenol

Quantifiable outcome

  • 8.4% net sales growth in Skin Health and Beauty segment Q1 2026
  • +4 more outcomes

Companies that use Kenvue

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Kenvue technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability9 records

Feature6 records

Kenvue partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • Fuel TransportminorStrategic or Co-development Partner · 2 June 2026Pilot program called Electric Loop (eLoop) testing electric freight delivery across select urban routes in Greater Toronto Area. Electric truck deployment on short-haul routes evaluating real-world operational performance, energy efficiency, and emissions impact in dense city conditions.
  • Asia Pacific Dental FederationminorStrategic or Co-development Partner · 25 May 2026Kenvue (makers of LISTERINE) supported landmark white paper on evidence-based daily oral self-care guidelines. Report highlights brushing reaches only 25% of mouth surfaces; therapeutic mouthwash reduces plaque by 25-50% and gum bleeding by up to 67.8%.
  • GreyparrotcoreTechnology or Integration · 20 May 2026Strategic collaboration leveraging Greyparrot's Deepnest AI platform to analyze and validate packaging performance in real-world recycling facilities in UK and US. Moves beyond theoretical design-for-recycling to actual recovery data, enabling packaging circularity improvements and EPR cost forecasting.
  • MicrosoftcoreTechnology or Integration · 7 May 2026Multi-year collaboration to modernize digital and data capabilities, aligning dermatologist education, AI-driven insights, and e-commerce execution to support Kenvue's innovation strategy.
  • Population Services International IndiaminorStrategic or Co-development Partner · 5 May 2026Collaboration on World Hand Hygiene Day and 'No Fear of Diarrhoea' initiative in Kanpur district, India. Health Department partnership distributing ORS packets and demonstrating proper handwashing techniques.
  • CVS Media Exchange (CMX)coreGTM or Marketing Partner · 1 May 2026Retail media partnership where Kenvue leverages CVS's CorIQ AI platform for media planning, real-time optimization, and measurement. Kenvue achieved 30% or greater lift in buyer conversion and basket size through the partnership.
  • Essex Bio-Technology LimitedminorStrategic or Co-development Partner · 23 March 2026Collaboration with Kenvue for consumer health products, announced alongside Essex's strategic partnerships for distribution including Beifushu entering Singapore market and MOU with Suzhou Industrial Park for life sciences accelerator.
  • Mayo CliniccoreStrategic or Co-development Partner · 10 March 2026Three-year research collaboration with Aveeno brand focusing on skin health science including preclinical and clinical investigations on skin longevity and regeneration. Builds on 80-year history of collaboration dating to 1945 when Musher brothers worked with Mayo Clinic to develop colloidal oatmeal treatments.
  • Kimberly-Clark CorporationcoreStrategic or Co-development Partner · 1 November 2025Kimberly-Clark announced plans to acquire Kenvue for approximately $48.7 billion enterprise value, creating a combined entity with ~$32 billion in revenue and $7 billion EBITDA pre-synergies. Deal approved by shareholders in January 2026 with CCI approval in India; expected to close H2 2026. Kenvue shareholders to receive $3.50 per share plus 0.14625 Kimberly-Clark shares per share.
  • Sonoma PharmaceuticalsminorOEM/ Whitelabel/ Licensing Partner · 1 October 2025Manufacturing and Supply Agreement for Microcyn technology-based products in US, effective October 2025 through March 2027 with potential extensions. Sonoma also launching new dermatology products and burn relief hydrogel in US retail stores.

Scale indicators16 records

Recent moves7 records

Expansion highlights5 records

Kenvue competitors and assessment

Company assessment

Direct peers

  • Church & Dwight: Church & Dwight (NYSE: CHD) operates in personal care, household, and specialty consumer health with brands including Orajel (oral pain relief competing with Anbesol/Tylenol Oral), Batiste (dry shampoo), and Trojan. The diversified consumer health orientation and North American retail distribution model align closely with Kenvue's approach.
  • Reckitt Benckiser: Reckitt (LSE: RKT) operates a Health segment (Mucinex, Delsym, Nurofen, Gaviscon) that directly competes with Kenvue's OTC franchise, plus Hygiene (Lysol, Dettol) and Home care. Reckitt is one of the closest pure-play comparables to Kenvue's OTC + hygiene orientation with similar pharmacy channel distribution.
  • L'Oréal: L'Oréal (EPA: OR) is the world's largest beauty company with dermatological brands (CeraVe, La Roche-Posay, Vichy) directly competing with Kenvue's Neutrogena and Aveeno franchises. The Skin Health and Beauty segment faces its most formidable competitor in L'Oréal's Active Cosmetics division, which has captured significant clinical skincare share.
  • Estée Lauder: Estée Lauder (NYSE: EL) operates premium skincare and beauty brands (Estée Lauder, Clinique, La Mer) competing with Kenvue's Neutrogena in mass-to-prestige skincare. While more premium-focused, Estée Lauder's dermatological skincare investments and global beauty distribution create direct competitive pressure on Kenvue's Skin Health and Beauty growth.
  • Haleon: Haleon (NYSE: HLN) is the world's other major pure-play consumer health company, spun off from GSK in 2022. It directly competes with Kenvue across OTC (Advil vs Tylenol, Centrum vs Flintstones), oral health (Sensodyne vs Listerine adjacent categories), and respiratory health (Panadol, Voltaren). Both companies share the same pure-play consumer health DNA, pharmacy distribution model, and brand-driven growth strategy.
  • Beiersdorf: Beiersdorf (XETRA: BEI) is a global skincare leader with Nivea, Eucerin, La Prairie, and Hansaplast directly competing with Kenvue's Neutrogena, Aveeno, and Band-Aid franchises. The dermatological positioning, OTC adjacency (Eucerin), and global skincare scale make Beiersdorf a direct peer in Skin Health and Beauty and wound care.
  • Bayer Consumer Health: Bayer's Consumer Health division (part of XETRA: BAYN) includes Aspirin, Claritin, Aleve, and Coppertone (now sold to Kenvue-aligned brands), directly competing with Kenvue's pain relief, allergy, and sun care franchises. The portfolio overlap in OTC analgesics and sun protection makes Bayer Consumer Health a direct comparable.
  • Colgate-Palmolive: Colgate-Palmolive (NYSE: CL) is the global oral care leader (Colgate, Tom's of Maine, meridol) directly competing with Kenvue's Listerine franchise, plus personal care (Palmolive, Softsoap) overlapping with Kenvue's body care brands. The business model alignment and shared retail channels make Colgate one of Kenvue's most direct competitors.

Broad incumbents

  • Procter & Gamble: P&G (NYSE: PG) is a diversified CPG incumbent with overlapping brands including Vicks (OTC cold), Pepto-Bismol (digestive), Align (probiotics), Oral-B (oral care), and Gillette (personal care). While P&G is much broader than Kenvue, the consumer health portfolio competes directly across most of Kenvue's Self Care and Essential Health segments.
  • Johnson & Johnson: Johnson & Johnson (NYSE: JNJ) was Kenvue's parent company until the May 2023 spin-off and continues to operate in adjacent consumer health-adjacent categories through its pharma and medtech segments. While J&J divested its consumer health business, the historical parent relationship, overlapping R&D heritage, and ongoing competitive dynamics make J&J a relevant broad incumbent comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Kenvue social profiles

Digital presence

Kenvue financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kenvue leadership team

Management profile

Number of profiles

Profiles13 records

Kenvue subsidiaries and ownership

Company hierarchy

Subsidiaries12 records

Kenvue funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kenvue M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kenvue

What does Kenvue do?

Kenvue is the world's largest pure-play consumer health company, manufacturing and marketing a portfolio of iconic over-the-counter medicines, skincare, oral care, baby care, and personal health brands. The company operates across three segments — Self Care (Tylenol, Motrin, Benadryl, Zyrtec, Nicorette, Imodium), Skin Health and Beauty (Neutrogena, Aveeno, OGX, Rogaine), and Essential Health (Listerine, Band-Aid, Johnson's Baby) — distributing products to approximately 1.2 billion consumers across more than 165 countries through retail pharmacies, drugstores, and e-commerce channels.

Is Kenvue a public or private company?

Kenvue is a public company. It is classified as public and is currently operating.

When was Kenvue founded?

Kenvue was founded in 2022. It employs 10,001+ people.

Where is Kenvue based?

Kenvue is headquartered in Summit, United States, in the North America region.

How does Kenvue make money?

Three revenue lines are on record. Self Care (OTC Medicines) is the primary driver. The others are skin Health and Beauty and essential Health.

Who are Kenvue's main competitors?

Direct peers on record are Church & Dwight, Reckitt Benckiser, L'Oréal, Estée Lauder, Haleon, Beiersdorf, Bayer Consumer Health and Colgate-Palmolive. Broad incumbents are Procter & Gamble and Johnson & Johnson.

Does Kenvue have an API?

No public API is recorded for Kenvue.

What industry is Kenvue in?

Kenvue's product category is Consumer Health Products. Its primary akta.pro industry code is CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges). Its NAICS code is 45619 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StIs Kimberly-Clark (KMB) Fully Priced After The Kenvue Deal?Kimberly-Clark's stock rose 10.6% over the past year, trading at a 38.4x P/E versus the sector's 17.7x and peers' 29.4x. The Kenvue deal and higher leverage raise integration costs and earnings stability concerns, while analysts see the premium valuation as already pricing in execution success.YahooKimberly Clark (KMB) Stock Looks Above Fair Value Following Its 11% RunKimberly-Clark shares have gained 10.6% over the past year, trading at a 38.4x P/E versus an industry average of 17.7x. The company's completed Kenvue acquisition, valued at $49 billion, is expected to shift future profits and cash flows. Analysts suggest the current price may be overvalued on earnings.Mirage NewsAllens Advises Kimberly-Clark on Kenvue Acquisition ClearanceAllens advised Kimberly-Clark on securing ACCC clearance for its US$48.7 billion acquisition of Kenvue under Australia's new mandatory merger control regime. The deal is the first global acquisition to obtain Phase 1 clearance with a structural remedy, involving divestiture of Kenvue's Carefree and Stayfree brands in Australia and New Zealand.WikipediaWikipediaJohnson & Johnson spun off its consumer health division as Kenvue in 2021, with the IPO on May 4, 2023, raising about $3.8 billion. Kenvue's shares traded at $26.90 on the first day, and the company was added to the S&P 500 Dividend Aristocrats in August 2023.247wallst3 Legacy Dividend Stocks That Never Go Out of StyleCoca-Cola, Procter & Gamble, and Kimberly-Clark are Dividend Kings with 64, 70, and 54 consecutive dividend raises, respectively. Coca-Cola and P&G have well-covered payouts, while Kimberly-Clark's yield is highest at 4.7% but its debt after the Kenvue deal leaves less margin for error.YahooKenvue (KVUE) Stock Still Looks Cheap Despite Its 27% RunKenvue's stock rose 26.9% over the past year, closing at $19.31, with a pending Kimberly-Clark takeover. A DCF model estimates intrinsic value above current price, citing $2.25B annual free cash flow and steady growth. The valuation question remains whether the price reflects underlying cash flows.The future of tradingDemocratic attorney general wins could reshape US lawsuits on abortion, immigration and moreDemocrats won state attorney general races in Georgia, Iowa, Ohio, Kansas, and Texas, potentially reshaping pending lawsuits on abortion, immigration, and other issues. Texas's new AG-elect could withdraw from cases against the FDA and Kenvue, while Georgia's AG-elect could affect abortion and voting rights litigation.Global Cosmetics NewsKimberly-Clark Completes Acquisition of KenvueKimberly-Clark completed its acquisition of Kenvue on 2 November 2026, combining consumer health, skincare, and personal care brands including Neutrogena, Johnson's Baby, Huggies, Listerine, Tylenol, and Kleenex. The deal targets about US$2.1 billion in annual run-rate synergies, with US$1.9 billion in cost savings within three years and US$500 million in additional profit.El CronistaKimberly-Clark cerró la compra de Kenvue: qué marcas quedan bajo el mismo techoKimberly-Clark completed its acquisition of Kenvue, operating as a single company from this week. The deal, valued at $48.7 billion, combines 10 brands each generating over $1 billion in revenue. The company now targets health and wellness categories, including baby care and women's health.TradingViewKMB: Adjusted EPS rose 17.2% as China headwinds and integration demands shaped the outlookKMB reported Q3 sales nearly flat while adjusted EPS rose 17.2% to $1.70, despite lower adjusted operating profit. The IFP gain lifted net income, but the completed Kenvue acquisition brings integration, financing, and execution risks.